MSP AND ITS RECEPTORS IN THE THERAPY OF AMYOTROPHIC LATERAL SCLEROSIS

摘要

Amyotrophic Lateral Sclerosis is a progressive motor neuron-degenerative disease that results in loss of voluntary muscle control. Impaired VapB function contributes to the pathology of ALS through reduced secretion of MSP, the 125 amino acid N-terminal domain of VapB. Administration of MSP or fragments or derivatives thereof rescues complications associated with reduced MSP secretion and is used to treat individuals with a neurological disorder or suspected of having a neurological disorder, such as ALS.